Table 1 Demographic and serological findings from 522 subjects and 614 serum samples tested for MOG-IgG
Diagnostic categories | Sample numbers | Patient numbers | Sex ratio (m:f) | Age (ys), median | MOG-IgG+, samples | MOG-IgG+, patients | MOG-IgG+, median§ | AQP4-IgG +, MOG-IgG + patients |
|---|---|---|---|---|---|---|---|---|
Group I | 386 | 300 | 1:2.4 | 39 | 95/386 (24.6%) | 50/300 (16.7%) | 1:640 | 0/50 (0%) |
“ON and/or MY”a | 281 | 202 | 95/281 (33.8%) | 50/202 (24.8%) | 1:640 | 0/50 (0%) | ||
“ON and MY”a | 79 | 54 | 39/79 (49.4%) | 22/54 (40.7%) | 1:1280 | 0/22 (0%) | ||
“mON/rON”a | 145 | 103 | 47/145 (32.4%) | 22/103 (21.4%) | 1:640 | 0/22 (0%) | ||
“mON”a | 69 | 66 | 10/69 (14.5%) | 9/66 (13.6%) | 1:800 | 0/9 (0%) | ||
“rON”a | 76 | 37 | 37/76 (48.7%) | 13/37 (35.1%) | 1:640 | 0/13 (0%) | ||
“MY” (all LETM)a | 57 | 45 | 9/57 (15.8%) | 6/45 (13.3%) | 1:2560 | 0/6 (0%) | ||
“MS”a | 58 | 54 | 0/58 (0%) | 0/54 (0%) | N.a. | N.a. | ||
“OND”a | 47 | 44 | 0/47 (0%) | 0/44 (0%) | N.a. | N.a. | ||
Group II | 89 | 83 | 1:1.9 | 46 | 0/89 (0%) | 0/83 (0%) | N.a. | 89/89 (100%) |
AQP4+ NMO | 59 | 56 | 0/59 (0%) | 0/56 (0%) | N.a. | 59/59 (100%) | ||
AQP4+ rON | 5 | 5 | 0/25 (0%) | 0/22 (0%) | N.a. | 25/25 (100%) | ||
AQP4+ LETM | 25 | 22 | 0/5 (0%) | 0/5 (0%) | N.a. | 5/5 (100%) | ||
Group III | 85 | 85 | 1:3 | 38 | 0/85 (0%) | 0/85 (0%) | N.a. | N.a. |
RRMS | 73 | 73 | 0/73 (0%) | 0/73 (0%) | N.a. | N.a. | ||
SPMS | 9 | 9 | 0/9 (0%) | 0/9 (0%) | N.a. | N.a. | ||
PPMS | 3 | 3 | 0/3 (0%) | 0/3 (0%) | N.a. | N.a. | ||
Group IV | 54 | 54 | 1:1.3 | 38 | 1/54 (1.9%) | 1/54 (1.9%) | 1:320* | 0/1 (0%) |
OND | 9 | 9 | 1/9 (11.1%) | 1/9 (11.1%) | 1:320* | 0/1 (0%) | ||
HC | 45 | 45 | 0/45 (0%) | 0/45 (0%) | N.a. | N.a. | ||
Group II–IV | 228 | 222 | 1:1.9 | 38 | 1/228 (0.5%) | 1/222 (0.5%) | 1:320* | 0/1 (0%) |
Total | 614 | 522 | 1:2.6 | 38 | 96/614 (15.6%) | 51/522 (9.8%) | 1:640 | 0/51 (0%) |